✦ LIBER ✦

Phase II study of 5′-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma

✍ Scribed by P. Alberto; M. Rozencweig; M. Clavel; P. Siegenthaler; F. Cavalli; S. Gundersen; U. Bruntsch; J. Renard; H. Pinedo

Publisher: Springer
Year: 1986
Tongue: English
Weight: 214 KB
Volume: 16
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00255292

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of epirubicin in advanced

Phase II study of epirubicin in advanced malignant melanoma

✍ Massimo Lopez; Carlo-Federico Perno; Paola Papaldo; Luigi Lauro; Fabrizio Ganzin 📂 Article 📅 1984 🏛 Springer US 🌐 English ⚖ 194 KB

A phase II study of combination therapy

A phase II study of combination therapy with 5′-deoxy-5-fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary foci

✍ Wasaburo Koizumi; Minoru Kurihara; Tadashi Sasai; Shigeaki Yoshida; Kimitomo Mor 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 513 KB

Background. 5'-Deoxy-5-fluorouridine (5'-DFUR, doxifluridine) is a recently developed prodrug of oral From the Japan Gastric Cancer Study Group,

Positive phase II study in the treatment

Positive phase II study in the treatment of advanced malignant melanoma with fotemustine

✍ Karin U. Schallreuter; Eberhard Wenzel; Frank W. Brassow; Jürgen Berger; Eckard 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 331 KB

A Phase II study of Bruceantin (NSC-165,

A Phase II study of Bruceantin (NSC-165, 563) in advanced malignant melanoma

✍ James C. Arseneau; Janet M. Wolter; Mario Kuperminc; John C. Ruckdeschel 📂 Article 📅 1983 🏛 Springer US 🌐 English ⚖ 240 KB

Interferon in combination with vinblasti

Interferon in combination with vinblastine in advanced malignant melanoma. A phase I–II study

✍ Stein Gundersen; A. Flokkmann 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 288 KB 👁 2 views

Nineteen patients with advanced malignant melanoma were treated with a combination of recombinant alfa-interferon (a-IFN) and vinblastine (VBL). The a-IFN was administered subcutaneously daily at an initial dose of 3 X lo6 IU escalating to a maximal dose of 9 X lo6 U daily for the first 10 weeks fol

Phase II study of subcutaneously adminis

Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma

✍ Bellet, Robert E. ;Catalano, R. B. ;Mastrangelo, Michael J. ;Berd, David 📂 Article 📅 1978 🏛 John Wiley and Sons 🌐 English ⚖ 268 KB

## Abstract Thirty (30) patients with advanced metastatic malignant melanoma refractory to DTIC (NSC‐45388) and a nitrosourea were treated with 5‐azacytidine (NSC‐102816). 5‐Azacytidine was administered subcutaneously at a dosage of 100 mg/m^2^/day for 10 days. Twenty‐six (26) patients were evaluab